News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement
|Articles|May 9, 2019

Managing Your Site Selection at the Portfolio Level

Advertisement

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Marcel Botha

What Impact will FDA's ANDA Prioritization Pilot have on Efficiency and Competitiveness?

ByMike Hollan,Marcel Botha
October 30th 2025
Pharmaceutical Executive

Pharmaceutical Executive Daily: Lilly and NVIDIA Create AI Supercomputer

ByNicholas Jacobus
October 29th 2025
Stock.adobe.com

FDA Announces New Biosimilar-Targeted Draft Guidance

ByMike Hollan
October 29th 2025
Stock.adobe.com

Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report

ByMike Hollan
October 29th 2025
Stock.adobe.com

Lilly Forms Partnership with NVIDIA to Create AI Supercomputer

ByNicholas Jacobus
October 29th 2025
Advertisement
Advertisement

Trending on PharmExec

1

Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report

2

Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings

3

FDA Announces New Biosimilar-Targeted Draft Guidance

4

Lilly Forms Partnership with NVIDIA to Create AI Supercomputer

5

Pharmaceutical Executive Daily: Lilly and NVIDIA Create AI Supercomputer

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us